3 Undervalued Pharmaceuticals Stocks for Thursday, May 02
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, May 02 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Friday, February 23
Discover the top 6 undervalued Pharmaceuticals stocks for Friday, February 23 based on AAII’s Stock Grades.Jack Gilleland
3 Undervalued Pharmaceuticals Stocks for Monday, November 06
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, November 06 based on AAII’s Stock Grades.Grace Malone
6 Undervalued Pharmaceuticals Stocks for Thursday, April 27
Discover the top 6 undervalued Pharmaceuticals stocks for Thursday, April 27 based on AAII’s Stock Grades.Jenna Brashear
4 Undervalued Pharmaceuticals Stocks for Wednesday, January 18
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, January 18 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.7 | $569.9 | 9% |
|
| Shares Out (Mil) | 11.7 | 44.8 | 23% |
|
| Institutional Ownership | 23.3% | 84.6% | 11% |
|
| Float (Mil) | 9.0 | 45.1 | 18% |
|
| Beta | 0.83 | 0.67 | 49% |
|
| Avg Daily Volume (000s) | 361 | 294 | 54% |
|
| Price Change (52-week) |
17.1% | 65.2% | 60% |
|
| Growth | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.3% | 6.7% | 77% |
|
| Net Income (5yr) | 0.9% | (2.0%) | 41% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.040) | ($0.160) | $0.320 | |
| Month Ago EPS | ($0.040) | ($0.160) | $0.320 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.110) | ($0.060) | na | |
| Year/Year Chg | (90.2%) | (84.6%) | (142.5%) | |
| Financials | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $43 | $230 | 19% |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 28% |
|
| EPS (TTM) | ($1.019) | ($0.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($6) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $7 | 27% |
|
| Enterprise Value (Q1) (Mil) | $15 | $493 | 9% |
|
| Valuation | BFRI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.41 | 2.89 | 58% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.3% | 65.9% | 87% |
|
| Net Margin | (25.7%) | (0.2%) | 15% |
|
| ROA | (53.6%) | (25.5%) | 11% |
|
| ROE | (339.0%) | (21.4%) | 2% |
|
| Liabilities to Assets | 75.5% | 35.5% | 71% |
|
| F-Score | 4 | 3 | 34% |
|
Biofrontera Inc. did not pass any screens on 7/30/2026.
